Finance entity
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention Alex Zhavoronkov, the most common co-covered peer. SK Biopharmaceuticals appears in 1 tracked Finance story from July 9, 2026. The tracked stories average 2 original sources each.
Last mentioned: Jul 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention Alex Zhavoronkov, the most common co-covered peer. SK Biopharmaceuticals appears in 1 tracked Finance story from July 9, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SK Biopharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
HKEX-listed Insilico Medicine (3696) projects H1 2026 revenue up 273%–287% to $106.5M, swinging to a net profit of up to $39.5M. The surprise profit alert positions the AI biotech as a high-growth, cash-generating investment.
Source: manilatimes.net · prnewswire.com
SK Biopharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
